Antengene Announces Five Presentations at the 2023 American Association for Cancer Research Meeting
- Written by PR Newswire
 |
- Five posters showcased progress with multiple preclinical and clinical programs, including ATG-008 (mTORC1/2 inhibitor), ATG-017 (ERK1/2 inhibitor), ATG-037 (CD73 inhibitor), ATG-031 (anti-CD24 monoclonal antibody) and ATG-034 (LILRB4 antagonist antibody)
- Clinical results showed promising efficacy of ATG-008 in patients with advanced HBV+ HCC, espec...
